BioCardia®, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: 6887216 titled, “Target Site Selection, Entry, and Update With Automatic Remote Image Annotation” with a patent term that will expire on January 8, 2034.
Lilly’s Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE:
